ArticleNeoplasia (New York, N.Y.)
Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.
Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 72 citations in OpenAlex.
- Article
- Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy.Ecancermedicalscience · 2017Review
- STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.Theranostics · 2017Article
- Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2012Article
- Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Cancer gene therapy · 2011Article
- Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.Journal of neuro-oncology · 2009Review
- Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts.British journal of cancer · 2007Article
- Gene therapy targeting to tumor endothelium.Cancer gene therapy · 2007Review
- An extraordinarily high level of IL-15 expression by a cell line transduced with a modified BMGneo vector displays hypoxic upregulation.Molecular biotechnology · 2006Article
- A novel chimeric promoter that is highly responsive to hypoxia and metals.Gene therapy · 2006Article
- A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons.Gene therapy · 2005Article
- A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas.Cancer science · 2005Article
- Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.Cancer gene therapy · 2005Article
- Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.Gene therapy · 2004Article
- Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization.Gene therapy · 2003Article
- Hypoxia-mediated tumour targeting.Gene therapy · 2003Article
- Transcriptional Targeting in Cancer Gene Therapy.Journal of biomedicine & biotechnology · 2003Article
- Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.Biotechnology advancesReview
- Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation.Neoplasia (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Previous studies have suggested that tumor hypoxia could be exploited for cancer gene therapy. Using hypoxia-responsive elements derived from the human vascular endothelial growth factor gene, we have generated vectors expressing a bacterial nitroreductase (NTR) gene that can activate the anticancer prodrug CB1954. Stable transfectants of human HT1080 tumor cells with hypoxia-inducible vectors were established with G418 selection. Hypoxic induction of NTR protein correlated with increased sensitivity to in vitro exposure of HT1080 cells to the prodrug. Growth delay assays were performed with established tumor xenografts derived from the same cells to detect the in vivo efficacy of CB1954 conversion to its cytotoxic form. Significant antitumor effects were achieved with intraperitoneal injections of CB1954 both in tumors that express NTR constitutively or with a hypoxia-inducible promoter. In addition, respiration of 10% 02 increased tumor hypoxia in vivo and enhanced the antitumor effects. Taken together, these results demonstrate that hypoxia-inducible vectors may be useful for tumor-selective gene therapy, although the problem of delivery of the vector to the tumors, particularly to the hypoxic cells in the tumors, is not addressed by these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.